Cargando…
Development of Effective Siglec-9 Antibodies Against Cancer
PURPOSE OF REVIEW: This study aims to review state-of-the-art advances in Siglec-9-directed antibodies and to highlight specific aspects of Siglec-9 antibodies that are suitable to mount anti-tumor immunity. RECENT FINDINGS: Controversies surrounding studies on Siglec-9 antibodies can confound futur...
Autores principales: | Wang, Jun Hui Shawn, Jiang, Nan, Jain, Amit, Lim, Jackwee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707166/ https://www.ncbi.nlm.nih.gov/pubmed/36445569 http://dx.doi.org/10.1007/s11912-022-01347-4 |
Ejemplares similares
-
WEE1 Inhibitor: Clinical Development
por: Kong, Anthony, et al.
Publicado: (2021) -
Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs
por: Joharatnam-Hogan, Nalinie, et al.
Publicado: (2021) -
Chronodisruption and Ambulatory Circadian Monitoring in Cancer Patients: Beyond the Body Clock
por: Almaida-Pagan, Pedro F., et al.
Publicado: (2022) -
Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin
por: Eisen, Tim, et al.
Publicado: (2014) -
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017)